

NOVEMBER 2017 FINANCIAL INFORMATION AS OF 30 SEPTEMBER 2017 UNLESS OTHERWISE NOTED

#### NBPE OVERVIEW

#### NBPE invests in private equity backed companies

#### **KEY HIGHLIGHTS**

Listing Date: 2007

Market Capitalisation (31/10/17): £484.6m

Net Asset Value (NAV): \$803.6m

**NAV per Share:** \$16.47 (£12.29)

**NAV Total Return USD / GBP** 

1 year: 15.2% / 11.9% 3 year: 31.5% / 59.1%

Share Price Total Return USD / GBP


1 year: 23.6% / 20.0% 3 year: 32.2% / 60.0%

2017 Avg. Daily Trading Volume: ~86k shares per day

Current share price (1/11/17): £10.00 (~19% discount)

Dividend Yield (on Share Price): 3.8%

#### **INVESTMENT TYPE BY FAIR VALUE**



Note: NBPE data as of 30 September 2017; GBP share price returns converted at daily GBP/USD close FX rates. Numbers may not sum due to rounding. All performance figures assume re-investment of dividends at NAV or closing share price on the exdividend date and reflect cumulative returns over the relevant time periods shown and are not annualised returns; share price return data based on the London Stock Exchange. Average trading volume represents daily average across London Stock Exchange, Euronext Amsterdam and over-the-counter trading platforms.

#### NBPE'S MANAGER: NEUBERGER BERMAN

Neuberger Berman manages over \$50 billion in Private Equity

#### PRIVATE EQUITY PLATFORM

Over \$50 billion of commitments managed<sup>(1)</sup>

# FUND INVESTMENTS Primary Secondary Co-Investments Private Debt Other Yielding Strategies NBPE Focus KEY HIGHLIGHTS

Industry Leadership: 30 years as a private equity investor; committed approximately \$5 billion annually(2) to private equity over the past three years

Active Fund Relationships: 400+ with over 270 funds reviewed each year

Experienced Investors: Expertise across fund investments, direct investments and income investments

Deep Team: Over 130 dedicated private equity investment professionals with extensive networks

Global Presence: Investment offices in New York, Dallas, Boston, London, Milan, Hong Kong and Bogota

<sup>1.</sup> Committed capital from inception through June 2017, including commitments in the process of documentation.

<sup>2.</sup> Average over the past three years (2014 - 2016).

#### NBPE'S VALUE PROPOSITION

NBPE provides exposure to direct private equity and debt investments underwritten alongside a diversified group of highquality private equity managers

#### INVESTMENTS ALONGSIDE HIGH QUALITY PRIVATE EQUITY SPONSORS

- Leverages the strength of the Neuberger Berman Platform: Neuberger Berman Private Equity has invested over ~\$2.5 billion in equity coinvestments and ~\$1.7 billion in debt investments over the last three years¹ with over 580 equity and over 460 debt opportunities reviewed
  during this period
- Well diversified (but not over diversified) direct investment portfolio: Portfolio of 114 direct investments over 50 different private equity sponsors
- Able to invest in all parts of the capital structure tactical shifts over time to the most compelling risk / reward opportunities
- Fee efficiency: Direct investments generally with single layer of fees<sup>2</sup>



Note: as of 30 September 2017. Private equity sponsors shown here are only a representative sample of those which NBPE has invested alongside. For a complete list of sponsors, see the appendix.

- Reflects investments made from 2014 2016.
- 2. In some cases, private equity sponsors may charge management fees and / or carried interest.

# NBPE NAV UPDATE

# September 2017 NAV per Share of \$16.47

#### **SUMMARY BALANCE SHEET**

30 September 2017 (Unaudited)	31 December 2016 (Audited)
\$138.2	\$139.0
549.2	474.9
687.4	613.9
121.2	153.4
808.7	767.3
101%	99%
67.0	93.7
-	<del>-</del>
-	(14.5)
(69.8)	(62.4)
(2.3)	(7.5)
\$803.6	\$776.6
\$16.47	\$15.91
£12.29	£12.89
\$16.97	-
	\$138.2 \$49.2 687.4 121.2 808.7 101% 67.0 - (69.8) (2.3) \$803.6 \$16.47 £12.29


Note: NBPE data as of 30 September 2017. Numbers may not sum due to rounding.

1. On 31 May 2017, the 2017 ZDP Shares were redeemed in full.

2. Based on 30 September 2017GBP/USD FX of \$1.339.

# NBPE PORTFOLIO DIVERSIFICATION


# Well diversified portfolio weighted to North American investments



Note: as of 30 September 2017. Numbers may not sum due to rounding. Please see endnotes for information on diversification calculations.

# PORTFOLIO INVESTMENT ACTIVITY & LIQUIDITY

#### Over \$1.0 billion of distributions to NBPE since 2014



Note: as of 30 September 2017. Numbers may not sum due to rounding.

# PERFORMANCE OVERVIEW BY INVESTMENT TYPE

# LTM, three year, and five year investment performance summary

#### NBPE PERFORMANCE MEASURED BY GROSS IRR

INVESTMENT TYPE	30 SEP 2017 FAIR VALUE (\$M)	LTM	THREE YEAR	FIVE YEAR
DIRECT EQUITY INVESTMENTS	\$549.2	22.3%	18.9%	22.1%
INCOME INVESTMENTS	\$138.2	10.3%	8.8%	11.2%
FUNDS	\$121.2	6.4%	2.3%	8.8%
TOTAL PORTFOLIO	\$808.7	16.8%	11.8%	14.4%

#### **KEY TAKEAWAYS:**

DIRECT EQUITY INVESTMENTS HAVE PERFORMED WELL ACROSS TIME PERIODS

INCOME INVESTMENTS ARE PERFORMING WELL AND HAVE PROVIDED STRONG YIELDS

FUNDS ARE NOW "TAIL-END" AND WINDING DOWN OVER TIME



DIRECT EQUITY INVESTMENTS

# NBPE DIRECT EQUITY INVESTMENT STRATEGY

Build and maintain a portfolio of direct private equity investments alongside leading private equity firms

- · High quality businesses
- · Reasonable investment valuations
- Co-investing alongside Managers in their core areas of expertise
- · Bias towards investments with shorter expected time to liquidity

#### **INVEST IN NEW DEALS**

#### **CO-INVEST "MID-LIFE" INTO EXISTING PRIVATE EQUITY PORTFOLIO COMPANIES**

# • Working alongside lead GPs VERTIV



#### ADD-ON ACQUISITIONS/ GROWTH CAPITAL

Provides primary equity for growth / M&A



#### **PARTIAL REALISATIONS**

• Provides liquidity to investors



#### **RECAPITALISATIONS**

Provides primary equity to recapitalise balance sheets



# NBPE DIRECT EQUITY PORTFOLIO

# NBPE has a well diversified direct equity portfolio, giving access to growing companies alongside high quality PE sponsors

NBPE DIRECT EQUITY INVESTMENTS
79 direct equity investments with \$549.2 million of fair value
DIVERSIFIED PORTFOLIO
Diversified by industry, geography, vintage year and sponsor
2017 GROWTH <sup>1</sup>
4% LTM Revenue growth / 7% LTM EBITDA growth
VALUATION & LEVERAGE <sup>1</sup>
11.0x EV / EBITDA & 4.7x Net Debt / EBITDA
2017 EXITS <sup>2</sup>
7 Exits generating a 4.4x gross multiple and 41% IRR

TOP TEN INVESTMENTS			
Investment Name	<u>Vintage</u>	<u>Industry</u>	FV (\$m)
Extraction Oil & Gas (NASDAQ: XOG)	2014	Energy	\$25.1
The Warranty Group	2014	Fin. Serv.	20.1
USI	2017	Fin. Serv.	20.0
ProAmpac	2016	Packaging	19.1
Staples	2017	Bus. Serv.	17.5
Gardner Denver (NYSE: GDI)	2013	Industrials	16.8
Vertiv	2016	Technology	15.6
Saguaro	2013	Energy	14.9
Engineering Ingegneria Informatica	2016	Technology	14.6
Financial Services Company*	2016	Fin. Serv.	14.2
TOP TEN INVESTMENTS			\$177.9

Note: As of 30 September 2017. \*Undisclosed company.

As of 30 June 2017. Portfolio company operating and valuation metrics are based on the most recently available (unaudited) financial information for each company. Where necessary, estimates were used, which include pro forma adjusted EBITDA and Revenue, annualised quarterly operating metrics and LTM periods as of 30/6/17 and 31/3/17. Data based on 46 traditional buyout companies valued based on EV/EBITDA; excludes companies based on other valuation metrics including book value, revenue multiples, discounted cash flow, latest round of financing and public share price.

<sup>2.</sup> Returns are presented on a "gross" basis (i.e. they do not reflect the management fees, carried interest, transaction costs and other expenses that may be paid by investors, which may be significant and may lower returns).

# NEW EQUITY INVESTMENTS IN 2017 YTD

# \$110.4 million invested in 13 new equity investments during 2017 YTD

INVESTMENT	INDUSTRY	SPONSOR	DESCRIPTION	THESIS
USI	Insurance	KKR	Insurance brokerage	Buy & Build. Defensive sector; strong cash generation
(MHS)	Business Services	Thomas H. Lee	Material handling systems for the courier industry	Secular industry growth trends
Branded Toy Company*	Consumer	Not disclosed	Specialty toy company	Diverse tangible growth strategies
ACCEDIAN NETWORKS	Technology	Bridge Growth	Network technology company	Technology differentiation & market trends
ENVIRONMENTAL TECHNOLOGIES	Industrials	AEA Small Business Fund	Distributor of aftermarket climate control components for vehicles	Buy & Build. Mid-life equity co-investment to fund an acquisition
HOSPITAL Bond Class Houthcare in Microbian	Healthcare	Quadria Capital	Leading hospital provider in Vietnam	Operational enhancement & expansion
ENVIRONMENTAL	Industrials	Gryphon Partners	Waste management services	Buy & Build. Mission critical, regulatory-driven services
Material Handling Services	Business Services	Harvest Partners	Outsourced service partner for material handling and service needs	Buy & Build. Fragmented market with strong consolidation drivers and multiple organic growth levers
Compliance Solutions Strategies	Business Services	CIP Capital	Provider of compliance solutions for the financial services industry	Organic and acquisition growth opportunities. Strong industry tailwinds
BYLIGHT Lighting the Path	Technology	Sagewind Partners	IT, cloud, cyber and infrastructure solutions	Strong industry tailwinds. Recurring contract base
STAPLES	Consumer / Business Svs	Sycamore Partners	Provider of office supplies through B2B platform & retail	Market leading, stable cash flow business
<b>West Marine</b>	Consumer	Monomoy Capital	Retailer of boat supplies	Strategy re-focus and business optimization
Mospitalist -	Healthcare	Gryphon Investors	Healthcare service provider	Sticky revenue base; attractive market

# **EQUITY REALISATIONS AND ANNOUNCED EXITS IN 2017 YTD**

# NBPE has continued to produce strong liquidity from its equity investments in 2017 YTD

· Global financial advisory and investment banking firm

INVESTMENT	VINTAGE	DESCRIPTION	OUTCOME
CAPSUGEL*	2011	<ul> <li>Developer and manufacturer of capsules for biopharmaceutical, health and nutrition industries</li> </ul>	Acquired by Lonza for \$5.5 bn
Deltek	2012	<ul> <li>Provider of enterprise software and information solutions for project-focused organisations</li> </ul>	Sold to Roper Technologies for \$2.8 bn
EVANS NETWORK OF COMPANIES	2012	<ul> <li>Market-leading provider of intermodal, flatbed, brokerage, dry van and other trucking services</li> </ul>	Sold to Calera Capital
Gabes	2012	<ul> <li>Off-price retailer offering well-known brands in apparel and accessories, operating 106 stores</li> </ul>	Sold to Warburg Pincus
VERTIV.	2016	Provider of data center infrastructure	Recapitalisation / divisional sale
rPatheon.	2014	Pharmaceutical contract development and manufacturing organisation	IPO in 2016; acquired by Thermo Fisher in 2017
<b>Ortholite</b> °	2014	Provider of high-performance insoles and related shoe components	Acquired by Trilantic North America
ÓTICAS CAROL	2013	Second largest eyewear retailer in Brazil	Acquired by Luxottica
SUBSEQUENT EXITS	<b>S</b> <sup>1</sup>		
<u>INVESTMENT</u>	<u>VINTAGE</u>	DESCRIPTION	OUTCOME
the warranty group	2014	Underwriter and administrator of extended warranties	Sold to Assurant for \$2.5 billion
<b>EVOQUA</b> WATER TECHNOLOGIES	2014	Water treatment technology, equipment and services	<ul> <li>IPO (NYSE:AQUA) at \$18 / share on 2/11/17</li> </ul>
Financial Services	2016	Clobal financial advisory and investment banking firm	Not displaced.

Note: As of 30 September 2017.

Company\*


2016

Not disclosed

<sup>\*</sup>Due to confidentiality provisions, company name cannot be disclosed.

#### **EQUITY EXITS & UPLIFT**

# NBPE has seen strong exits and valuation uplift relative to carrying values



<sup>1.</sup> As of 30 September 2017. Includes full exits only. Excludes partial exits, recapitalisations and IPOs until the stock is fully exited. Year represents the year of final exit. Exit year for public companies determined by the date of the final cash flow. Proceeds include funds that are currently in escrow, but are expected to be received. Returns are presented on a "gross" basis (i.e. they do not reflect the management fees, carried interest, transaction costs and other expenses that may be paid by investors, which may be significant and may lower returns).

<sup>2.</sup> Ás of 30 September 2017. Analysis includes five IPOs, one partial exits, and nineteen full direct equity investment exits since January 2015. For investments which completed an IPO, the value is based on the closing share price on the IPO date; however NBPE remains subject to customary IPO lockup restrictions. Returns are presented on a "gross" basis (i.e. they do not reflect the management fees, carried interest, transaction costs and other expenses that may be paid by investors, which may be significant and may lower returns).



#### CASE STUDY: VERTIV

#### Acquisition of Network Power business from Emerson alongside Platinum Equity

#### **SUMMARY**

Investment date	November 2016
Lead investor	Platinum Equity
Industry	Industrials
Sourcing	NB Private Equity Relationship

#### **COMPANY OVERVIEW**

- Platinum Equity acquired the Network Power business from Emerson and rebranded as Vertiv
- Vertiv (FKA Emerson) provides mission-critical infrastructure technologies for vital applications in data centers, communication networks, and commercial and industrial environments
  - Major customers include AT&T, China Mobile, Microsoft, Ericsson and Facebook
- Vertiv is headquartered in Ohio and has ~20,000 employees worldwide

#### **INVESTMENT THESIS**

- Build on broad portfolio offering: product and services for power, thermal and IT management capabilities
- Drive transformation: emphasise growth, speed, agility, and profitability
- Identify and purse add-ons: rationalise complex systems landscape through multiple acquisitions


#### **INVESTMENT UPDATE**

- Focus on operational, financial and M&A capabilities to support growth and innovation
- Sale of ASCO division to Schneider Electric in July 2017 for \$1.25 billion to help position Vertiv for a greater focus on core business


# PUBLIC MARKET VS. PRIVATE EQUITY VALUATIONS

#### Private equity valuations remain at a discount to the public markets on average

#### U.S. PUBLIC VS. PRIVATE VALUATIONS




#### **EUROPEAN PUBLIC VS. PRIVATE VALUATIONS**




# PRIVATE EQUITY MARKET – GLOBAL BUYOUT EXIT OVERVIEW

# A large proportion of companies remain active in older portfolios, as average holding periods have increased

#### PROPORTION OF ACTIVE AND REALISED PRIVATE EQUITY-BACKED BUYOUT DEALS BY INVESTMENT YEAR, 2006 - 2016



#### **AVERAGE GLOBAL BUYOUT HOLDING PERIODS, 2006 - 2016**



Source: 2017 Pregin Global Private Equity & Venture Capital Report.



**INCOME INVESTMENTS** 

# NBPE INCOME INVESTMENT STRATEGY

#### Since inception, robust deal flow and selectivity have led to strong and stable performance

- Invest in the debt of private equity backed businesses
- Use the knowledge and relationships of the NB Private Equity platform for sourcing and due diligence
- Invest on a Primary and Secondary basis

#### INVEST IN THE DEBT OF PRIVATE EQUITY BACKED COMPANIES

# First / Second Lien ProAmpac Digital River OPTIV SUNGARD Schumachergroup Schumachergroup FLEXER DUBOIS WATER TECHNOLOGIES DEBOT PRIMARY Mezzanine Mezzanine Mezzanine

#### **CORPORATE DEBT - SECONDARY**

Mispricings or Dislocations

**Misunderstood Credits** 

- Target smaller, less liquid issuers
- Rigorous fundamental private equity due diligence
- Long-term investment capabilities
- Target equity-like returns in fixed income

#### NBPE INCOME PORTFOLIO

# The NBPE income portfolio is well diversified, performing well and has a reasonable average level of total leverage

#### NBPE INCOME INVESTMENTS

35 income investments with \$138.2 million of fair value

#### CASH YIELD & LEVERAGE STATISTICS<sup>1</sup>

- 10.3% cash yield / 12.0% estimated yield to maturity
- 6.1x total leverage / 4.3x senior leverage
- 87% of fair value in floating rate debt
- 57% dividend coverage from portfolio cash yield

#### **KEY STATS<sup>2</sup>**

- 72% are in asset light companies
- 92% are in a market leading position<sup>3</sup>
- 57% are in companies with a >40% equity cushion
- 95% are in companies with a >20% equity cushion
- 53% are in companies with a >25% EBITDA margin
- 100% are in performing credits with no covenant issues

TOP TEN INVESTMENTS*			
Investment Name	<u>Industry</u>	Cash Yield	<u>FV (\$m)</u>
Linxens	Technology	9.7%	10.0
Schumacher Group	Healthcare	9.9%	9.7
Carestream Dental	Healthcare	9.6%	9.2
Dubois Chemical	Industrials	9.4%	9.1
ProAmpac	Packaging	9.8%	6.0
Taylor Precision Products	Consumer	12.6%	5.9
Central Security Group	Consumer	10.7%	5.9
Optiv	Technology	8.4%	5.7
Galco Industrial	Industrials	10.4%	5.3
Sungard	Technology	9.8%	4.9
TOP TEN INVESTMENTS			\$71.7

Note: As of 30 September 2017. \*Top 10 Investments exclude credit opportunities investments.

Leverage statistics exclude small business loan programs, credit opportunities and healthcare credit investments. Based on portfolio company data as of 30 June 2017. Small business loan programs are excluded from yield calculations but are at an interest rate at least at the rate stated above.

Debt key statistics exclude healthcare credit investments and small business loan portfolios.

<sup>3.</sup> Companies have a leading market position in their industry or niche based on NB's due diligence.

# NEW INCOME INVESTMENTS IN 2017 YTD

#### \$43.2 million invested in nine new income investments during 2017 YTD **NEW INCOME INVESTMENTS<sup>1</sup>**

INVESTMENT	INDUSTRY	EQUITY SPONSOR	INVESTED (\$MM)	DESCRIPTION
DuBois	Industrials	Jordan Group	\$9.0	<ul> <li>L+8.00%, 1% L Floor</li> <li>Second lien</li> <li>Producer of chemicals for the manufacturing industry</li> </ul>
ÖPTIV	Technology	KKR	\$6.0	<ul> <li>L+7.25%, 1% L Floor</li> <li>Second lien</li> <li>Cyber security solutions provider</li> </ul>
SUNGARD Public Sector	Technology	Vista Equity Partners	\$4.9	<ul> <li>L+8.50%, 1% L Floor</li> <li>First lien</li> <li>Provider of tech solutions that address public safety and administration needs for education and governments</li> </ul>
D blue nile.  THE SOURCE OF BRILLIANCE TO	Consumer	Bain Capital	\$3.6	<ul><li>L+6.50%, 1% L Floor</li><li>Second lien</li><li>Online jewelry retailer</li></ul>
Oh Hospitalist	Healthcare	Gryphon Investors	\$3.8	<ul><li>L+8.50%, 1% L Floor</li><li>Second lien</li><li>Healthcare service provider</li></ul>
EPIC	Insurance	Oak Hill Capital	\$2.8	<ul><li>L+9.25%, 1% L Floor</li><li>Second lien</li><li>Insurance provider</li></ul>
Note: As of 30 September 2017.  1. Excludes two undisclosed investments made three	Communications  ough the NB Credit Opportunities progr	Oak Hill Capital	\$1.3	<ul> <li>L+8.00%, 1% L Floor</li> <li>Second lien</li> <li>Fiber optic network provider</li> </ul>




DIVIDENDS, CAPITAL POSITION & PERFORMANCE

#### DIVIDENDS AND CAPITAL POSITION

#### Dividends strongly covered by cash distributions and yield from the income portfolio

# DIVIDENDS CAPITAL POSITION<sup>1</sup>



# CASH POSITION

\$217.0 million of cash & available credit facility

**UNFUNDED COMMITMENTS** 

\$19.9 million of adjusted unfunded commitments

**COMMITMENT COVERAGE** 

1,088% adjusted commitment coverage

Note: See endnote #3 for important information related to the dividend. Total yield (inclusive of PIK interest) represents the return (IRR) from this reporting period to the maturity of the investment. As of 30 September 2017.

Unfunded commitments are adjusted by funds past their investment period and amounts which NBPE has the right to terminate if it so chooses.

<sup>2.</sup> Based on the company's most recent dividend and the London Stock Exchange closing share price of £9.93 on 30 September 2017 and the 30 September 2017 NAV of \$16.47 per share.

# HISTORIC PERFORMANCE

# Strong NAV and share price performance over the short, medium and long term

#### CUMULATIVE RETURNS OVER TIME<sup>1</sup>

TOTAL RETURN	YTD 2017	ONE YEAR	THREE YEAR	FIVE YEAR	SINCE INCEPTION
NET ASSET VALUE USD / GBP	6.8% / -1.6%	15.2% / 11.9%	31.5% / 59.1%	70.6% / 105.1%	94.9% / 197.4%
SHARE PRICE USD / GBP	15.7% / 6.5%	23.6% / 20.0%	32.2% / 60.0%	124.5% / 169.9%	66.4% / 154.0%


Note: NAV data as of 30 September 2017. NBPE share price data based on the London Stock Exchange as of 30 September. Prior to 30 June 2009, NBPE was only listed on the Euronext Amsterdam exchange; the Euronext Amsterdam exchange share price has been substituted for performance calculations prior to this date. GBP share price returns converted at daily GBP/USD close FX rates.

All performance figures assume re-investment of dividends at NAV or closing share price on the ex-divided date and reflect cumulative returns over the relevant time periods shown and are not annualised returns.

# NAV & SHARE PRICE DEVELOPMENT

On a total return basis, including dividends, NAV per Share has increased 6.8% year to date<sup>1</sup>

#### NBPE NAV & SHARE PRICE DEVELOPMENT (SEPTEMBER 2016 – SEPTEMBER 2017)



Note: Based on London Stock Exchange price data. As of 1 November 2017. USD share price based on daily close GBP/USD FX rate. 1. As of 30 September 2017.

#### NBPE – EFFICIENT PRIVATE EQUITY

We believe NBPE offers access to a diverse private equity and income portfolio at a lower cost than many other listed private equity vehicles

# Listed Fund of Funds

- Charge double layer of fees
  - Often 1.5% 2.0% management fee on committed capital and 20% carry at the underlying fund level in addition to fund of funds fees & carry
- · Hyper-diversified portfolios
- Potential for significant capital structure risk from any over commitment strategy and / or return dilution from cash drag

# Listed Direct Funds

- Single layer of fees, but at a higher level
  - 1.5% management fee on NAV (or NAV + committed capital) and 15 20% carry
- · Concentrated lead manager risk and often more concentrated portfolio
- Multiple "direct" vehicles invest in third party funds and have multiple layers of fees

#### **NBPE**

- · Single layer of fees on direct investments
  - 1.5% on NAV and 7.5% performance fee
- Appropriately diversified with multiple top tier managers
- · Low over commitment risk

# ATTRACTIVE VALUE PROPOSITION

#### We believe NBPE offers a compelling investment opportunity


- · Capital appreciation and growth from equity investments
- Income through an attractive dividend, supported by the cash yield from the income portfolio and investment realisations
- · Strong capital structure and commitment coverage
- Private equity exposure with attractive fee structure direct investments in portfolio typically feature lower all-in fees than investing directly into LP funds

NEUBERGER BERMAN

# **APPENDIX**

# FUND INVESTMENT PORTFOLIO LIQUIDITY


NBPE's fund portfolio has continued to produce strong liquidity while becoming an increasingly immaterial component of the overall portfolio



# CURRENT EQUITY PORTFOLIO VALUATION BY YEAR

The equity co-investment portfolio is held at a 1.2x multiple of cost

#### **EQUITY PORTFOLIO VALUATION BY VINTAGE YEAR**



Note: as of 30 September 2017.

# **EQUITY INVESTMENTS**

Company Name	Asset Class	Investment Date	Lead Sponsor	Fair Value	% of NBPE NAV
Accedian	Growth / Venture	Apr-17	Bridge Growth Partners	\$10.0	1.2%
Acteon	Large-cap Buyout	Dec-12	KKR	1.2	0.2%
Alex & Ani	Mid-cap Buyout	May-15	Lion Capital	4.3	0.5%
American Dental Partners, Inc.	Mid-cap Buyout	Feb-12	JLL Partners	5.2	0.6%
ARUHI Corporation	Mid-cap Buyout	Oct-14	Carlyle Group	9.0	1.1%
Aster / DM Healthcare	Mid-cap Buyout	Jun-14	Olympus Capital	7.0	0.9%
Avava	Large-cap Buyout	Oct-07	TPG / Silver Lake Partners	0.0	0.0%
Berlin Packaging	Mid-cap Buyout	Oct-14	Oak Hill Capital Partners	6.6	0.8%
Black Knight Financial Services	Large-cap Buyout	Dec-13	Thomas H. Lee	11.8	1.5%
Boa Vista	Mid-cap Buyout	Nov-12	TMG Capital	1.4	0.2%
Branded Toy Company*	Mid-cap Buyout	Jul-17	Not Disclosed	10.6	1.3%
Brightview	Large-cap Buyout	Dec-13	KKR	7.0	0.9%
Bylight	Mid-cap Buyout	Jun-17	Sagewind Partners	2.5	0.3%
Centro	Growth / Venture	Jun-15	FTV Capital	3.5	0.4%
Compliance Solutions Strategies	Mid-cap Buyout	Apr-17	CIP Capital	3.9	0.5%
Concord Bio	Growth / Venture	Jun-16	Quadria Capital	3.6	0.4%
Connector Company*	Growth / Venture	Oct-15	Not Disclosed	4.0	0.5%
Consilio	Growth / Venture	Jul-15	Shamrock Capital	11.0	1.4%
Corona Industrials	Mid-cap Buyout	Jun-14	Victoria Capital	1.8	0.2%
Counsyl	Growth / Venture	Jul-14	Pilot Growth	5.5	0.7%
CSC Service Works	Mid-cap Buyout	Mar-15	Pamplona Capital	6.5	0.8%
Digital River (Equity)	Mid-cap Buyout	Feb-15	Siris Capital	9.0	1.1%
Ellucian	Large-cap Buyout	Sep-15	TPG Capital	7.0	0.9%
Engineering Ingegneria Informatica	Mid-cap Buyout	May-16	NB Renaissance	14.6	1.8%
Evoqua Equity	Mid-cap Buyout	Jan-14	AEA Investors	10.7	1.3%
Extraction Oil & Gas	Mid-cap Buyout	May-14	Yorktown Partners	25.1	3.1%
Fairmount Minerals	Mid-cap Buyout	Aug-10	American Securities Partners	1.0	0.1%
Final Site	Mid-cap Buyout	Nov-16	Bridge Growth Partners	12.5	1.6%
Financial Services Company*	Large-cap Buyout	Sep-16	Not Disclosed	14.2	1.8%
First Data	Large-cap Buyout	Sep-07	KKR	3.5	0.4%
Formation Energy	Mid-cap Buyout	Jul-13	Lindsay Goldberg	1.1	0.1%
Fortress	Mid-cap Buyout	Jun-17	Quadria Capital	7.0	0.9%
Galco Industrials Equity	Special Situations	May-14	AEA Investors	0.8	0.1%
Gardner Denver, Inc.	Large-cap Buyout	Jul-13	KKR	16.8	2.1%
GC Services	Mid-cap Buyout	Jan-16	Owner Resource Group	5.9	0.7%
Genetic Testing Company - Equity*	Special Situations	Jun-13	Not Disclosed	8.7	1.1%
Hilsinger	Mid-cap Buyout	May-14	Blue Point Capital	4.9	0.6%
Incipio	Growth / Venture	Feb-16	Goode Partners	0.8	0.1%
Inflection Energy	Mid-cap Buyout	Oct-14	Chambers Energy	4.4	0.6%
Innovation Group	Large-cap Buyout	Dec-15	Carlyle Group	0.8	0.1%
Into University Partnerships	Mid-cap Buyout	Apr-13	Leeds Equity Partners	1.5	0.2%
J.Crew Group	Large-cap Buyout	Mar-11	TPG / Leonard Green	0.4	0.0%
	Lange dap Dayout		. 1 0 / 20011010 010011	٠	0.070

Company Name	Asset Class	Investment Date	Lead Sponsor	Fair Value	% of NBPE NAV
Kyobo Life Insurance Co.	Mid-cap Buyout	Dec-07	Corsair Capital Partners	2.0	0.3%
Lasko Products	Special Situations	Nov-16	Comvest Partners	8.4	1.0%
Leaseplan	Mid-cap Buyout	Apr-16	TDR Capital	10.0	1.2%
LGC	Large-cap Buyout	Mar-16	KKR	12.6	1.6%
Looking Glass	Growth / Venture	Feb-15	Alsop Louie	7.1	0.9%
Marquee Brands	Special Situations	Dec-14	Neuberger Berman	13.8	1.7%
West Marine	Mid-cap Buyout	Sep-17	Monomoy Capital	7.0	0.9%
Material Handling Systems	Mid-cap Buyout	Apr-17	Thomas H. Lee	11.3	1.4%
MBI Energy	Mid-cap Buyout	Jun-14	Lindsay Goldberg	0.1	0.0%
MHS	Mid-cap Buyout	Mar-17	Harvest Partners	4.9	0.6%
Mills Fleet Farms	Large-cap Buyout	Feb-16	KKR	4.4	0.5%
OB Hospitalist Group	Mid-cap Buyout	Aug-17	Gryphon Partners	0.4	0.1%
Omega Environmental Technologies	Mid-cap Buyout	Feb-17	AEA Investors	9.3	1.2%
Petsmart	Large-cap Buyout	Jun-15	BC Partners	9.9	1.2%
ProAmpac	Mid-cap Buyout	Nov-16	Pritzker Group	19.1	2.4%
ProMach	Mid-cap Buyout	Nov-14	AEA Investors	6.2	0.8%
Prosper	Growth / Venture	Apr-15	Multiple Sponsors	1.8	0.2%
RiverBed	Mid-cap Buyout	Feb-15	Thoma Bravo	9.5	1.2%
Saguaro	Mid-cap Buyout	Jul-13	Pine Brook	14.9	1.8%
Shelf Drilling	Mid-cap Buyout	Feb-13	Castle Harlan Partners	1.3	0.2%
Snagajob	Growth / Venture	Jun-16	NewSpring Capital	4.6	0.6%
Solace Systems	Growth / Venture	Apr-16	Bridge Growth Partners	7.3	0.9%
SolarWinds	Large-cap Buyout	Feb-16	Thoma Bravo	8.4	1.0%
Specialty Drug Pharma. Company*	Mid-cap Buyout	Oct-15	Not Disclosed	0.8	0.1%
Staples	Large-cap Buyout	Sep-17	Sycamore Partners	17.5	2.2%
Standard Aero	Mid-cap Buyout	Jun-15	Veritas Capital	7.8	1.0%
Stratus Technologies	Mid-cap Buyout	Apr-14	Siris Capital	2.8	0.4%
Syniverse Technologies	Large-cap Buyout	Feb-11	Carlyle Group	3.0	0.4%
Taylor Precision Products	Mid-cap Buyout	Jul-12	Centre Partners	2.7	0.3%
Technology Company (Encryption App)*	Growth / Venture	Aug-14	Not Disclosed	1.5	0.2%
The Warranty Group	Large-cap Buyout	Jul-14	TPG	20.1	2.5%
Univar	Large-cap Buyout	Nov-10	Clayton, Dublier & Rice	0.7	0.1%
USI	Large-cap Buyout	Jun-17	KKR	20.0	2.5%
Velocidi	Growth / Venture	Dec-16	Pilot Growth	2.0	0.2%
Vencore	Mid-cap Buyout	Nov-10	Veritas Capital	7.3	0.9%
Vertiv	Special Situations	Nov-16	Platinum Equity	15.6	1.9%
Wind River Environmental	Mid-cap Buyout	Apr-17	Gryphon Partners	5.9	0.7%
Net Other Assets, incl. Escrow / (Liabilities)	a oup Dayout	, p	Organism division	\$0.3	n.a.
Total Equity Co-investment Portfolio				\$549.2	68.3%

Note: As of 30 September 2017.

<sup>\*</sup> Due to confidentiality provisions, company name cannot be disclosed.

# **INCOME INVESTMENTS**

NVESTMENT NAME								
Part	INVESTMENT NAME	SECURITY DETAILS			FAIR VALUE <sup>1</sup>			
Part	Corporate Private Debt Investments							
First   First   First   Second Lien (1-8.0% Cash, 1% L. Floor, 1% OD)   Sep-17   Dec-22   1.4   9.4%   8.9%   9.8%   Cash the Land Cash 1% L. Floor, 3% OD)   Sep-17   Sep-25   2.9   10.0%   10.7%   11.0%   Cash the Land Cash 1.0% L. Floor, 3% OD)   Sep-17   Sep-25   9.2   9.4%   9.6%   9.6%   9.8%   9.8%   0.0%   9.8%   0.0%   9.8%   0.0%	•							
Epit Insurance		Second Lien (L+8.0% Cash, 1% L Floor, 1.5% OID)	Sep-17	Dec-22	1.4	9.4%	8.9%	9.8%
Second Lien (L. 4. 67% Cash, 1 1 k L. Floor, 2 1 k C. Floor,		,		Sep-25		10.6%	10.7%	11.0%
Dubois Chemical   Second lien (L+8.09% Cash, 1% L Floor, 1% OID)   Mar-17   Mar-25   9.1   9.4%   9.4%   9.7%	Carestream Dental	Second Lien (L+8.0% Cash, 1% L Floor, 3% OID)	Sep-17	Sep-25	9.2	9.4%	9.6%	9.8%
Blue Nile	OB Hospitalist	Second Lien (L+8.5% Cash, 1% L Floor, 2% OID)	Aug-17	Aug-25	3.6	9.9%	10.8%	12.1%
Second Lien (1-7.25%, 1% Floor, 0.5% OID)	Dubois Chemical	Second lien (L+8.00% Cash, 1% L Floor, 1% OID)	Mar-17	Mar-25	9.1	9.4%	9.4%	9.7%
Sungard   Second Lien (1-8.50%, 1% Floor, 1.0% OID)   Feb.17   Jan-25   4.9   9.9%   9.8%   10.3%	Blue Nile	First Lien (L+6.50% Cash, 1% L Floor, 3% OID)	Mar-17	Feb-23	3.6	7.9%	7.9%	8.4%
2015   ProAmpac   Second Lien (L+8.50%, 1% L Floor)   Nov-16   Oct-24   6.0   9.9%   9.8%   10.1%	Optiv	Second Lien (L+7.25%, 1% Floor, 0.5% OID)	Feb-17	Feb-25	5.7	8.6%	8.4%	8.7%
ProAmpace   Second Lien (L+8.50%, 1% L Floor)   Nov-16   Oct-24   6.0   9.9%   9.8%   10.1%	Sungard	Second Lien (L+8.50%, 1% Floor, 1.0% OID)	Feb-17	Jan-25	4.9	9.9%	9.8%	10.3%
2015   Linvens   Second lien (L+8.25% Cash, 1.0% L Floor, 1% OID)   Oct-15   Oct-23   10.0   9.6%   9.7%   10.1%	2016							
Linxens   Second lien (L+8.25% Cash, 1.0% L Floor, 1% OID)	ProAmpac	Second Lien (L+8.50%, 1% L Floor)	Nov-16	Oct-24	6.0	9.9%	9.8%	10.1%
Schumacher Group   Second lien (L+8.5% Cash, 1.0% L Floor, 1% OID)   Oct-15   Oct-23   9.7   9.9%   9.9%   10.4%	2015							
Funding Circle	Linxens	Second lien (L+8.25% Cash, 1.0% L Floor, 1% OID)	Oct-15	Oct-23	10.0	9.6%	9.7%	10.1%
Digital River Debt   First lien (L+5.75% Cash, 1.0% L Floor, 1% OID)   Jan-15   Feb-21   1.8   7.1%   7.2%   7.3%     Digital River Debt   Second lien (L+11.0% Cash, 1.0% L Floor, 1% OID)   Jan-15   Feb-22   1.1   12.4%   11.6%   12.9%     2014   Security Group   Second lien (L+9.0% Cash, 1.% L Floor, 5% OID)   Nov-14   Cet-21   5.9   10.4%   10.7%   10.9%     Galco Industrial Electronics   Sr. sub notes (10.75% Cash, 1.25% PIK, 1.5% OID)   May-14   May-21   5.3   12.0%   10.4%   11.7%     2013   Taylor Precision Products   Sr. sub notes (13% Cash, 1.5% OID)   Nov-13   May-19   5.9   13.0%   12.6%   11.4%     P2 Energy Solutions   Second lien (L+8.00% Cash, 1.0% L Floor, 1% OID)   Nov-13   May-21   4.6   9.4%   10.3%   13.5%     Total Corporate Private Debt Investments Fair Value   S95.2   9.9%   9.9%   10.4%     Total Credit Opportunities Investments   S34.9   9.1%   11.2%   11.70%     Healthcare Credit Investments*   Sa4.9   9.1%   11.2%   11.2%   11.0%     2016   Generic Pharmaceutical Company   Senior secured term loan (L+5.375%, 1% Floor)   Jan-16   Jan-23   - 6.7%   7.2%   8.6%     2014   Convertible Notes (Specially Pharmaceuticals)   Convertible notes (4.5% Cash)   Apr-14   May-20   - 4.5%   6.7%   4.6%     2015   Feb-14   Feb-19   - 12.0%   NIM   NIM     Term Loan (Medical Diagnostics)   Senior secured loan (first Lien, 10% Cash, 1.75% fee)   Jan-14   De-18   - 10.5%   10.5%   10.5%   11.1%     2013   Term Loan (Genetic Testing)   Senior secured loan (First Lien, 10% Cash, 1% Fee)   Jun-13   Jun-18   - 10.0%   9.9%   10.5%     Total Healthcare Credit Investments Fair Value   S8.2   8.3%   10.0%   7.6%     Total Healthcare Credit Investments Fair Value   S8.2   8.3%   10.0%   7.6%     Total Healthcare Credit Investments Fair Value   S8.2   8.3%   10.0%   7.6%     Total Healthcare Credit Investments Fair Value   S8.2   8.3%   10.0%   7.6%     Total Healthcare Credit Investments Fair Value   S8.2   8.3%   10.0%   7.6%     Total Healthcare Credit Investments Fair Value   S8.2   8.3%   10.0%   7.6%     To	Schumacher Group	Second lien (L+8.5% Cash, 1.0% L Floor, 1% OID)	Oct-15	Oct-23	9.7	9.9%	9.9%	10.4%
Digital River Debt   Second lien (L+11.0% Cash, 1.0% L Floor, 1% OID)   Jan-15   Feb-22   1.1   12.4%   11.6%   12.9%	Funding Circle	Portfolio of small business loans	Jan-15	N/A	4.3	N/A	N/A	N/A
2014   Central Security Group   Second lien (L+9.0% Cash, 1% L Floor, 5% OID)   Nov-14   Oct-21   5.9   10.4%   10.7%   10.9%   Galco Industrial Electronics   Sr. sub notes (10.75% Cash, 1.25% PIK, 1.5% OID)   May-14   May-21   5.3   12.0%   10.4%   11.7%   11	Digital River Debt	First lien (L+5.75% Cash, 1.0% L Floor, 1% OID)	Jan-15	Feb-21	1.8	7.1%	7.2%	7.3%
Central Security Group   Second lien (L+9.0% Cash, 1% L Floor, 5% OID)   Nov-14   Oct-21   5.9   10.4%   10.7%   10.9%	Digital River Debt	Second lien (L+11.0% Cash, 1.0% L Floor, 1% OID)	Jan-15	Feb-22	1.1	12.4%	11.6%	12.9%
Salco Industrial Electronics   Sr. sub notes (10.75% Cash, 1.25% PIK, 1.5% OID)   May-14   May-21   5.3   12.0%   10.4%   11.7%	2014							
Taylor Precision Products   Sr. sub notes (13% Cash, 1.5% OIID)   Nov-13   May-19   5.9   13.0%   12.6%   11.4%     P2 Energy Solutions   Second lien (L+8.00% Cash, 1.0% L Floor, 1% OID)   Nov-13   May-21   4.6   9.4%   10.3%   13.5%     Total Corporate Private Debt Investments Fair Value   S95.2   9.9%   9.9%   10.4%     Total Credit Opportunities Investments   S34.9   9.1%   11.2%   17.0%     Healthcare Credit Investments*   S4.9   Senior secured term loan (L + 5.375%, 1% Floor)   Jan-16   Jan-23   Senior Secured term loan (L + 5.375%, 1% Floor)   Jan-16   Jan-23   Senior Secured term loan (L + 5.375%, 1% Floor)   Senior Secured term loan (L + 5.375%, 1% Floor)   Jan-16   Jan-23   Senior Secured term loan (L + 5.375%, 1% Floor)   Jan-16   Jan-23   Senior Secured term loan (L + 5.375%, 1% Floor)   Jan-16   Jan-23   Senior Secured term loan (L + 5.375%, 1% Floor)   Jan-16   Jan-23   Senior Secured term loan (Senior Secured term loan (Seni	Central Security Group	Second lien (L+9.0% Cash, 1% L Floor, 5% OID)	Nov-14	Oct-21	5.9	10.4%	10.7%	10.9%
Taylor Precision Products   Sr. sub notes (13% Cash, 1.5% OID)   Nov-13   May-19   5.9   13.0%   12.6%   11.4%     P2 Energy Solutions   Second lien (L+8.00% Cash, 1.0% L Floor, 1% OID)   Nov-13   May-21   4.6   9.4%   10.3%   13.5%     Total Corporate Private Debt Investments Fair Value   595.2   9.9%   9.9%   10.4%     Total Credit Opportunities Investments   \$34.9   9.1%   11.2%   17.0%     Healthcare Credit Investments	Galco Industrial Electronics	Sr. sub notes (10.75% Cash, 1.25% PIK, 1.5% OID)	May-14	May-21	5.3	12.0%	10.4%	11.7%
P2 Energy Solutions   Second lien (L+8.00% Cash, 1.0% L Floor, 1% OID)   Nov-13   May-21   4.6   9.4%   10.3%   13.5%     Total Corporate Private Debt Investments Fair Value   \$95.2   9.9%   9.9%   10.4%     Total Credit Opportunities Investments   \$34.9   9.1%   11.2%   17.0%     Healthcare Credit Investments	2013							
Total Corporate Private Debt Investments Fair Value   \$95.2   9.9%   9.9%   10.4%     Total Credit Opportunities Investments   \$34.9   9.1%   11.2%   17.0%     Healthcare Credit Investments*	Taylor Precision Products	Sr. sub notes (13% Cash, 1.5% OID)	Nov-13	May-19	5.9	13.0%	12.6%	11.4%
Total Credit Opportunities Investments	P2 Energy Solutions	Second lien (L+8.00% Cash, 1.0% L Floor, 1% OID)	Nov-13	May-21	4.6	9.4%	10.3%	13.5%
Healthcare Credit Investments*	Total Corporate Private Debt Investments Fair Value				\$95.2	9.9%	9.9%	10.4%
Senior Secured term loan (L + 5.375%, 1% Floor)   Jan-16   Jan-23   - 6.7%   7.2%   8.6%	Total Credit Opportunities Investments				\$34.9	9.1%	11.2%	17.0%
Ceneric Pharmaceutical Company   Senior secured term loan (L + 5.375%, 1% Floor)   Jan-16   Jan-23   - 6.7%   7.2%   8.6%	Healthcare Credit Investments*							
2014   Convertible Notes (Specialty Pharmaceuticals)	2016							
Convertible Notes (Specialty Pharmaceuticals)         Convertible notes (4.5% Cash)         Apr-14         May-20         -         4.5%         6.7%         4.6%           Term Loan (Specialty PCP and Pediatric Pharmaceuticals)         Senior secured loan (first lien, 12% cash, 0.75% fee)         Feb-14         Feb-19         -         12.0%         N/M         N/M           Term Loan (Medical Diagnostics)         Senior secured loan (10.5% Cash)         Jan-14         Dec-18         -         10.5%         11.1%           2013         Term Loan (Genetic Testing)         Senior secured loan (First Lien, 10% Cash, 1% Fee)         Jun-13         Jun-18         -         10.0%         9.9%         10.5%           Royalty Notes (Hormone Therapy)         Royalty backed note         Apr-11         N/A         -         N/A         N/M         N/M           Total Healthcare Credit Investments Fair Value         \$8.2         8.3%         10.0%         7.6%	Generic Pharmaceutical Company	Senior secured term loan (L + 5.375%, 1% Floor)	Jan-16	Jan-23	-	6.7%	7.2%	8.6%
Term Loan (Specialty PCP and Pediatric Pharmaceuticals)   Senior secured loan (first lien, 12% cash, 0.75% fee)   Feb-14   Feb-19   - 12.0%   N/M   N/M     Term Loan (Medical Diagnostics)   Senior secured loan (10.5% Cash)   Jan-14   Dec-18   - 10.5%   10.5%   11.1%     2013	2014							
Term Loan (Medical Diagnostics)	Convertible Notes (Specialty Pharmaceuticals)	Convertible notes (4.5% Cash)	Apr-14	May-20	-	4.5%	6.7%	4.6%
2013           Term Loan (Genetic Testing)         Senior secured loan (First Lien, 10% Cash, 1% Fee)         Jun-13         Jun-18         -         10.0%         9.9%         10.5%           Royalty Notes (Hormone Therapy)         Royalty backed note         Apr-11         N/A         -         N/A         N/M         N/M           Total Healthcare Credit Investments Fair Value         \$8.2         8.3%         10.0%         7.6%	Term Loan (Specialty PCP and Pediatric Pharmaceuticals)	Senior secured loan (first lien, 12% cash, 0.75% fee)	Feb-14	Feb-19	-	12.0%	N/M	N/M
Term Loan (Genetic Testing)         Senior secured loan (First Lien, 10% Cash, 1% Fee)         Jun-13         Jun-18         -         10.0%         9.9%         10.5%           Royalty Notes (Hormone Therapy)         Royalty backed note         Apr-11         N/A         -         N/A         N/M         N/M           Total Healthcare Credit Investments Fair Value         \$8.2         8.3%         10.0%         7.6%	Term Loan (Medical Diagnostics)	Senior secured loan (10.5% Cash)	Jan-14	Dec-18	-	10.5%	10.5%	11.1%
Royalty Notes (Hormone Therapy)         Royalty backed note         Apr-11         N/A         -         N/A         N/M         N/M           Total Healthcare Credit Investments Fair Value         \$8.2         8.3%         10.0%         7.6%	2013							
Total Healthcare Credit Investments Fair Value \$8.2 8.3% 10.0% 7.6%	Term Loan (Genetic Testing)	Senior secured loan (First Lien, 10% Cash, 1% Fee)	Jun-13	Jun-18	-	10.0%	9.9%	10.5%
	Royalty Notes (Hormone Therapy)	Royalty backed note	Apr-11	N/A	-	N/A	N/M	N/M
Total Income Portfolio Fair Value \$138.2 9.5% 10.3% 12.0%	Total Healthcare Credit Investments Fair Value				\$8.2	8.3%	10.0%	7.6%
	Total Income Portfolio Fair Value				\$138.2	9.5%	10.3%	12.0%

Note: As of 30 September 2017.

1. See endnote #4 for important information on the income investment portfolio.

\* Due to confidentiality provisions, company name cannot be disclosed.

# **FUND INVESTMENTS**

(\$ in millions) Fund Investments	Asset Class	Vintage Year	Fair Value	Unfunded Commitment <sup>1</sup>
Catalyst Fund III	Special Situations Funds	2011	\$14.0	\$1.2
NB Crossroads Fund XVIII Mid-cap Buyout	Mid-cap Buyout Funds	Fund XVIII	10.7	7.1
Bertram Growth Capital II	Growth / Venture Funds	2010	9.6	1.8
NG Capital Partners	Growth / Venture Funds	2010	6.9	0.4
Platinum Equity Capital Partners II	Special Situations Funds	2007	6.6	3.3
Bertram Growth Capital I	Growth / Venture Funds	2007	6.2	1.0
Corsair III Financial Services Capital Partners	Mid-cap Buyout Funds	2007	5.8	0.9
NB Crossroads Fund XVIII Venture Capital	Growth / Venture Funds	Fund XVIII	5.8	1.7
NB Crossroads Fund XVII	Fund XVII (Diversified)	Fund XVII	5.8	1.7
Sun Capital Partners V	Special Situations Funds	2007	5.3	1.0
DBAG Expansion Capital Fund	Growth / Venture Funds	2012	3.7	1.0
NB Crossroads Fund XVIII Large-cap Buyout	Large-cap Buyout Funds	Fund XVIII	3.4	2.2
Avista Capital Partners	Mid-cap Buyout Funds	2006	3.3	0.1
NB Crossroads Fund XVIII Special Situations	Special Situations Funds	Fund XVIII	3.2	0.9
NB Fund of Funds Secondary 2009	Mid-cap Buyout Funds	2009	2.8	0.6
Sankaty Credit Opportunities III	Special Situations Funds	2007	2.7	-
OCM Principal Opportunities Fund IV	Mid-cap Buyout Funds	2007	2.7	2.0
17 Other Fund Investments (< \$3m Individually)			\$22.5	\$12.0
Total Fund Investments			\$121.2	\$39.0

# TRADING INFORMATION

Trading Symbol:	Class A Ordinary Shares: NBPE
Exchanges:	London Stock Exchange & Euronext Amsterdam
Traded Currency:	GBP (LSE); USD (Euronext)
Bloomberg:	NBPE NA, NBPE LN
Reuters:	NBPE.AS, NBPE.L
ISIN:	GG00B1ZBD492
COMMON:	030991001

Trading Symbol:	2022 ZDPs: NBPP
Exchanges:	London Stock Exchange
Base Currency:	GBP
Bloomberg:	NBPP:LN
ISIN:	GG00BD0FRW63
SEDOL:	BD0FRW6
Gross Redemption Yield at Issuance:	4.0%
Share Life:	30 September 2022
Final Capital Entitlement:	126.74p

# **CONTACT INFORMATION**

Registered Office:	NB Private Equity Partners Limited P.O. Box 225 Heritage Hall, Le Marchant Street St. Peter Port, Guernsey GY1 4HY Channel Islands Tel: +44.(0).1481.716.000
Investment Manager:	NB Alternatives Advisers LLC 325 N. Saint Paul Street Suite 4900 Dallas, TX 75201 United States of America
Investor Relations:	Web: www.nbprivateequitypartners.com Email: IR_NBPE@nb.com Tel: +1.214.647.9593
Media Relations:	Neustria Partners Nick Henderson Tel: +44.20.3021.2583

Corporate Brokers:	Stifel Nicolaus Neil Winward Tel: +44.20.7710.7600  Jefferies International Limited Gary Gould/Stuart Klein Tel: +44.20.7029.8766
Research Analysts:	Stifel Nicolaus- Iain Scouller Email: iain.scouller@stifel.com
	Jefferies – Matthew Hose Email: matt.hose@jefferies.com
	J.P. Morgan Cazenove – Christopher Brown Email: christopher.brown@jpmorgan.com
	Canaccord Genuity – Alan Brierley Email: abrierley@canaccordgenuity.com
	Fidante – Tom Skinner Email: tskinner@fidante.com
	Liberum Capital – Coner Finn Email: coner.finn@liberumcapital.com
	Numis – Charles Cade & Sarah Lewandowski Email: c.cade@numis.com
	Winterflood – Simon Elliott Email: simon.elliott@wins.co.uk

#### **ENDNOTES**

- 1. The diversification analysis by geography, industry and vintage is based on the fair value of underlying fund investments and direct/co-investments; the diversification analysis for company size is based on the fair value of the underlying direct/co-investments and the fair value of funds with a focus on the company size described. Determinations regarding geography, industry, vintage and company size represent the Investment Manager's estimates. Accordingly, the actual diversification of our investment portfolio and the diversification of our investment portfolio on an ongoing basis may vary from the foregoing information. For the NB Alternatives Direct Co-investment Program and the NB Healthcare Credit Investment Program commitments, total exposure only reflects the funded investments to date. Unfunded amounts and unfunded percentages within each of these programs are excluded from the analysis, as capital deployment is opportunistic and cannot be accurately forecast at this time.
- 2. Guidance regarding NBPE's future portfolio and performance is a target only and not a profit forecast. There can be no assurance that this target will be met or that the Company will make any future distributions whatsoever. Any such changes will be notified to shareholders through a regulatory information service. NBPE's Board of Directors will continue to evaluate the Company's financial position, annual dividend target and the timing of future dividends. Future dividend payments will be announced by NBPE after the Board of Directors have completed such evaluation.
- 3. Yield to maturities represent the return (IRR) from this reporting period to maturity of the investment. Includes a portfolio of small business loans at an interest rate at least at the rate stated above but not included in the yield calculations. The Taylor Precision Products debt notes currently pay 13% cash, but issuer has the option to pay 11% and 2% PIK.
- 4. Actual unfunded commitments are \$253.7 million at 30 September 2017, corresponding to actual over commitment of \$36.7 million and an actual commitment coverage ratio of 85.5%. Unfunded adjustments include removing unfunded commitments to funds past their investment period (although some amount may be called for future follow-ons or expenses), and amounts which can be terminated by NBPE if it so chooses.

# LEGAL DISCLAIMER

THE CONTENTS OF THIS DOCUMENT AND THE PRESENTATION ARE STRICTLY CONFIDENTIAL AND MAY NOT BE COPIED, DISTRIBUTED, PUBLISHED OR REPRODUCED IN WHOLE OR IN PART, OR DISCLOSED OR DISTRIBUTED BY RECIPIENTS TO ANY OTHER PERSON. ANY RECIPIENT OF THIS DOCUMENT AGREES TO KEEP PERMANENTLY CONFIDENTIAL ALL INFORMATION HEREIN NOT ALREADY IN THE PUBLIC DOMAIN.

This document and the presentation are not for release, publication or distribution (directly or indirectly) in or into the United States, Canada, Australia or Japan or to any "US person" as defined in Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act") or into any other jurisdiction where applicable laws prohibit its release, distribution or publication. It does not constitute an offer of securities for sale anywhere in the world, including in or into the United States, Canada, Australia or Japan. No recipient may distribute, or make available, this document or the presentation (directly or indirectly) to any other person. Recipients of this document and the presentation should inform themselves about and observe any applicable legal requirements in their jurisdictions. In particular, the distribution of this document and the presentation may in certain jurisdictions be restricted by law. Accordingly, recipients represent that they are able to receive this document and relating presentation without contravention of any applicable legal or regulatory restrictions in the jurisdiction in which they reside or conduct business.

This document and the presentation have been prepared by NB Private Equity Partners Limited ("NBPE") and NB Alternatives Advisers LLC (the "Investment Manager"). No member of the Neuberger Berman Group nor any of their respective directors, officers, employees, advisors, representatives, or other agents makes or has been authorised to make any representation or warranties (express or implied) in relation to NBPE or as to the truth, accuracy or completeness of this document or the presentation, or any other written or oral statement provided. In particular, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on any projections, targets, estimates or forecasts contained in this document or the presentation and nothing in this document or the presentation is or should be relied on as a promise or representation as to the future. The name "Neuberger Berman" is used interchangeably throughout these materials for a number of entities that are part of, or are associated with, the Neuberger Berman Group and when used in this notice includes all such entities.

This document does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any decision in respect of NBPE or other evaluation of any securities of NBPE or any other entity and should not be considered as a recommendation that any investor should subscribe for or purchase any such securities. Neither the issue of this document nor the presentation nor any part of their contents constitutes an offer to sell or invitation to purchase any securities of NBPE or any other entity or any persons holding securities of NBPE and no information set out in this document or the presentation or referred to in other written or oral information is intended to form the basis of any contract of sale, investment decision or any decision to purchase any securities referred to in it.

The information contained in this document is given at the date of its publication (unless otherwise marked) and is subject to updating, revision and amendment. No reliance may be placed for any purpose whatsoever on the information of opinions contained in this document or on its completeness, accuracy or fairness. The contents of this document have not been approved by any competent regulatory or supervisory authority.

This document, any presentation made in conjunction with this document and any accompanying materials (the "Information Materials") are made available for information purposes only. The Information Materials, which are not a prospectus or listing particulars or an admission document, do not contain any representations, do not constitute or form part of any offer or invitation to sell or transfer, or to underwrite, subscribe for or acquire, any shares or other securities, and do not constitute or form any part of any solicitation of any such offer or invitation, nor shall they are or any part of them or the fact of their distribution form the basis of or be relied upon in connection with any contract therefore, and do not constitute a recommendation regarding the securities of NBPE.

Neither NBPE nor Neuberger Berman gives any undertaking to provide the recipient with access to any additional information, or to update this document, the presentation or any additional information, or to correct any inaccuracies in it which may become apparent and the distribution of this document and the presentation shall not be deemed to be any form of commitment on the part of NBPE, the Investment Manager or Neuberger Berman to proceed with any transaction.

#### LEGAL DISCLAIMER

THE PROMOTION OF NBPE AND THE DISTRIBUTION OF THIS DOCUMENT AND THE PRESENTATION IN THE UNITED KINGDOM IS RESTRICTED BY LAW. ACCORDINGLY, THIS COMMUNICATION IS DIRECTED ONLY AT (I) PERSONS OUTSIDE THE UNITED KINGDOM TO WHOM IT IS LAWFUL TO COMMUNICATE TO, OR (II) PERSONS HAVING PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS WHO FALL WITHIN THE DEFINITION OF "INVESTMENT PROFESSIONALS" IN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (AS AMENDED), OR (III) HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS AND PARTNERSHIPS AND TRUSTESS OF HIGH VALUE TRUSTS AS DESCRIBED IN ARTICLE 49(2) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (AS AMENDED); PROVIDED THAT IN THE CASE OF PERSONS FALLING INTO CATEGORIES (II) OR (III), THE COMMUNICATION IS ONLY DIRECTED AT PERSONS WHO ARE ALSO "QUALIFIED INVESTORS" AS DEFINED IN SECTION 86 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (EACH A "RELEVANT PERSON"). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS COMMUNICATION RELATES IS AVAILABLE ONLY TO AND WILL BE ENGAGED IN ONLY WITH SUCH RELEVANT PERSONS. PERSONS WITHIN THE UNITED KINGDOM WHO RECEIVE THIS COMMUNICATION. YOU REPRESENT AND AGREE THAT YOU ARE A RELEVANT PERSON.

NBPE HAS NOT BEEN, AND HAS NO INTENTION TO BE, REGISTERED UNDER THE U.S. INVESTMENT COMPANY ACT OF 1940, AS AMENDED (THE "INVESTMENT COMPANY ACT") AND INVESTORS WILL NOT BE ENTITLED TO THE BENEFITS OF THAT ACT. THE SECURITIES DESCRIBED IN THIS DOCUMENT HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT. CONSEQUENTLY, SUCH SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS (AS SUCH TERM IS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) UNLESS SUCH SECURITIES ARE REGISTERED UNDER THE SECURITIES ACT OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENT OF THE SECURITIES ACT IS AVAILABLE. NO PUBLIC OFFERING OF THE SECURITIES IS BEING MADE IN THE UNITED STATES.

PROSPECTIVE INVESTORS SHOULD TAKE NOTE THAT ANY SECURITIES MAY NOT BE ACQUIRED BY INVESTORS USING ASSETS OF ANY RETIREMENT PLAN OR PENSION PLAN THAT IS SUBJECT TO PART 4 OF SUBTITLE B OF TITLE I OF THE UNITED STATES EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AS AMENDED ("ERISA") OR SECTION 4975 OF THE UNITED STATES INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE "CODE"), ENTITIES WHOSE UNDERLYING ASSETS ARE CONSIDERED TO INCLUDE "PLAN ASSETS" OF ANY SUCH RETIREMENT PLAN OR PENSION PLAN, OR ANY GOVERNMENTAL PLAN, CHURCH PLAN, NON-U.S. PLAN OR OTHER INVESTOR SUBJECT TO ANY STATE, LOCAL, NON-U.S. OR OTHER LAWS OR REGULATIONS SIMILAR TO TITLE I OR ERISA OR SECTION 4975 OF THE CODE OR THAT WOULD HAVE THE EFFECT OF THE REGULATIONS ISSUED BY THE UNITED STATES DEPARTMENT OF LABOR SET FORTH AT 29 CFR SECTION 2510.3-101, AS MODIFIED BY SECTION 3(42) OF ERISA.

THE MERITS OR SUITABILITY OF ANY SECURITIES MUST BE INDEPENDENTLY DETERMINED BY THE RECIPIENT ON THE BASIS OF ITS OWN INVESTIGATION AND EVALUATION OF NBPE, THE INVESTMENT MANAGER, AND NEUBERGER BERMAN. ANY SUCH DETERMINATION SHOULD INVOLVE, AMONG OTHER THINGS, AN ASSESSMENT OF THE LEGAL, TAX, ACCOUNTING, REGULATORY, FINANCIAL, CREDIT AND OTHER RELATED ASPECTS OF THE SECURITIES. RECIPIENTS OF THIS DOCUMENT AND THE PRESENTATION ARE RECOMMENDED TO SEEK THEIR OWN INDEPENDENT LEGAL, TAX, FINANCIAL AND OTHER ADVICE AND SHOULD RELY SOLELY ON THEIR OWN JUDGMENT, REVIEW AND ANALYSIS IN EVALUATING NBPE, THE INVESTMENT MANAGER, AND NEUBERGER BERMAN, AND THEIR BUSINESS AND AFFAIRS.

THIS DOCUMENT AND THE PRESENTATION MAY CONTAIN CERTAIN FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS RELATE TO EXPECTATIONS, BELIEFS, PROJECTIONS, FUTURE PLANS AND STRATEGIES, ANTICIPATED EVENTS OR TRENDS AND SIMILAR EXPRESSIONS CONCERNING MATTERS THAT ARE NOT HISTORICAL FACTS. IN SOME CASES, FORWARD-LOOKING STATEMENTS CAN BE INDENTIFIED BY TERMS SUCH AS "ANTICIPATE", BELIEVE", "COULD", "ESTIMATE", "EXPECT", "INTEND", "MAY", "PLAN", "POTENTIAL", "SHOULD", "WILL", AND "WOULD", OR THE NEGATIVE OF THOSE TERMS OR OTHER COMPARABLE TERMINOLOGY. THE FORWARD-LOOKING STATEMENTS ARE BASED ON NBPE'S AND/OR NEUBERGER BERMAN'S BELIEFS, ASSUMPTIONS AND EXPECTATIONS OF FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL IN FORWARD-LOOKING STATEMENTS OF FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL IN FORWARD-LOOKING STATEMENTS OF FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL IN FORWARD-LOOKING STATEMENTS OF FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL IN FORWARD-LOOKING STATEMENTS OF FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL IN FORWARD-LOOKING STATEMENTS OR NEUBERGER BERMAN'S CONTROL. IF A CHANGE OCCURS, NBPE'S BUSINESS, FINANCIAL CONDITION, LIQUIDITY AND RESULTS OF OPERATIONS MAY VARY MATERIALLY FROM THOSE EXPRESSED IN FORWARD-LOOKING STATEMENTS. SOME OF THE FACTORS THAT COULD CAUSE ACTUAL RESULTS TO VARY FROM THOSE EXPRESSED IN FORWARD-LOOKING STATEMENTS, INCLUDE, BUT ARE NOT LIMITED TO: THE FACTORS DESCRIBED IN THIS DOCUMENT AND THE PRESENTATION; THE RATE AT WHICH NBPE DEPLOYS ITS CAPITAL IN INVESTMENTS AND ACHIEVES EXPECTED RATES OF RETURN; NBPE'S AND THE INVESTMENT MANAGER'S ABILITY TO EXECUTE NBPE'S INVESTMENT STRATEGY, INCLUDING THROUGH THE IDENTIFICATION OF A SUFFICIENT NUMBER OF APPROPRIATE INVESTMENTS; THE CONTINUED AFFILIATION OF THE INVESTMENT SHAT THE NBPE MAKES; CHANGES IN FINANCIAL MARKETS AND THE MARKET PRICE OF NBPE'S SHARES.

IN FINANCIAL MARKETS. INTEREST RATES OR INDUSTRY. GENERAL ECONOMIC

BY THEIR NATURE, FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES BECAUSE THEY RELATE TO EVENTS, AND DEPEND ON CIRCUMSTANCES THAT MAY OR MAY NOT OCCUR IN THE FUTURE. FORWARD-LOOKING STATEMENTS ARE NOT GUARANTEES OF FUTURE PERFORMANCE. ANY FORWARD-LOOKING STATEMENTS ARE ONLY MADE AS AT THE DATE OF THIS DOCUMENT AND THE PRESENTATION, AND NEITHER NBPE NOR THE INVESTMENT MANAGER ASSUMES ANY OBLIGATION TO UPDATE FORWARD-LOOKING STATEMENTS SET FORTH IN THIS DOCUMENT WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS, OR OTHER WISE, EXCEPT AS REQUIRED BY LAW OR OTHER APPLICABLE REGULATION. IN LIGHT OF THESE RISKS, UNCERTAINTIES, AND ASSUMPTIONS, THE EVENTS DESCRIBED BY ANY SUCH FORWARD-LOOKING STATEMENTS BY THESE CAUTIONARY FACTORS. PLEASE KEEP THIS CAUTIONARY NOTE IN MIND WHILE READING THIS DOCUMENT.

#### LEGAL DISCLAIMER

BY ACCEPTING AND READING THIS DOCUMENT AND/OR ATTENDING THE PRESENTATION TO WHICH THIS DOCUMENT RELATES YOU WILL BE DEEMED TO HAVE REPRESENTED, WARRANTED AND UNDERTAKEN FOR THE BENEFIT OF NBPE, THE INVESTMENT MANAGER, NEUBERGER BERMAN AND OTHERS THAT (A) YOU ARE OUTSIDE OF THE UNITED STATES AND ARE AN "INVESTMENT PROFESSIONAL" (AS DEFINED ABOVE), (B) YOU HAVE READ AND AGREE TO COMPLY WITH THE CONTENTS OF THIS NOTICE, YOU WILL KEEP THE INFORMATION IN THIS DOCUMENT AND DELIVERED DURING ANY PRESENTATION OR CONTAINTED IN ANY ACCOMPANYING DOCUMENT AND ALL INFORMATION ABOUT NEUBERGER BERMAN CONFIDENTIAL, AND WILL NOT REPRODUCE OR DISTRIBUTE, IN WHOLE OR IN PART, (DIRECTLY OR INDIRECTLY) ANY SUCH INFORMATION, UNTIL SUCH INFORMATION HAS BEEN MADE PUBLICLY AVAILABLE AND TAKE ALL REASONABLE STEPS TO PRESERVE SUCH CONFIDENTIALITY, AND (C) YOU ARE PERMITTED, IN ACCORDANCE WITH APPLICABLE LAWS, TO RECEIVE SUCH INFORMATION.

NBPE IS ESTABLISHED AS A CLOSED-END INVESTMENT COMPANY IN GUERNSEY AND THE COMPANY IS SUBJECT TO THE NETHERLANDS FINANCIAL SUPERVISION ACT (WET OP HET FINANCIEL TOEZICHT, "WFT"), AS A LISTED ENTITY (UITGEVENDE INSTELLING) AS DEFINED IN SECTION 1:1 OF THE WFT. ALL INVESTMENTS ARE SUBJECT TO RISK. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE RETURNS. PROSPECTIVE INVESTORS ARE ADVISED TO SEEK EXPERT LEGAL, FINANCIAL, TAX AND OTHER PROFESSIONAL ADVICE BEFORE MAKING ANY INVESTMENT DECISION. THE VALUE OF INVESTMENTS MAY FLUCTUATE. RESULTS ACHIEVED IN THE PAST ARE NO GUARANTEE OF FUTURE RESULTS.

THIS DOCUMENT IS ISSUED BY NBPE WHOSE REGISTERED ADDRESS IS AT HERITAGE HALL, PO BOX 225, LE MARCHANT STREET, ST. PETER PORT, GUERNSEY GY1 4HY. NB ALTERNATIVES ADVISERS LLC IS A REGISTERED INVESTMENT ADVISER IN THE UNITED STATES. NEUBERGER BERMAN IS A REGISTERED TRADEMARK, ALL RIGHTS RESERVED. ©2017 NB ALTERNATIVES ADVISERS LLC.